Concert Pharmaceuticals Inc (CNCE)

NASDAQ

Currency in USD

8.370

0.000(0.00%)

Closed03/03

Fair Value

Day's Range

8.350

8.550

52 wk Range

8.350

8.550

CNCE Income Statement

Featured here, the Income Statement (earnings report) for Concert Pharmaceuticals Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2012

31/12

2013

31/12

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

Total Revenues

0.06

10.51

1.08

7.9

32.58

Total Revenues Growth

-64.37%

+16,843.55%

-89.75%

+633.7%

+312.28%

Cost Of Revenues

30.22

43.15

59.82

61.62

87.56

Gross Profit

-30.16

-32.64

-58.74

-53.72

-54.98

Gross Profit Growth

+18.06%

-8.23%

-79.94%

+8.54%

-2.34%

Gross Profit Margin %

-48,646.77%

-310.75%

-5,453.95%

-679.85%

-168.75%

Other Operating Expenses, Total

21.02

22.94

20.28

18.93

22.53

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+46.39%	+9.14%	-11.61%	-6.66%	+19.05%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	21.02	22.94	20.28	18.93	22.53
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

-51.18

-55.58

-79.02

-72.65

-77.51

Operating Income Growth

-0.03%

-8.6%

-42.15%

+8.06%

-6.69%

EBIT Margin %

-82,548.39%

-529.12%

-7,336.58%

-919.35%

-237.92%

Net Interest Expenses

0.52

2.79

2.99

1.2

0.05

Net Interest Expenses Growth

+16.55%

+434.93%

+7.18%

-59.76%

-96.17%

Interest Expense, Total

-0.82

-

-

-

-

Interest And Investment Income

1.34

2.79

2.99

1.2

0.05

Other Non Operating Expenses, Total

143.83

0.01

0.01

-

-2.08

EBT, Excl. Unusual Items

93.17

-52.79

-76.02

-71.45

-79.55

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-1.43

-

-

-

-

EBT, Incl. Unusual Items

95.34

-55.71

-78.17

-74.85

-80.05

EBT, Incl. Unusual Items Growth

+287.97%

-158.43%

-40.31%

+4.24%

-6.95%

EBT, Incl. Unusual Items Margin

153,772.58%

-530.33%

-7,257.75%

-947.24%

-245.72%

Income Tax Expense

-0.3

0.31

-

-0.09

-

Net Income to Company

95.64

-56.02

-78.17

-74.77

-80.05

Minority Interest

-

-

-

-

-

Net Income

95.64

-56.02

-78.17

-74.77

-80.05

Net Income Growth

+288.56%

-158.58%

-39.52%

+4.35%

-7.07%

Net Income Margin %

154,256.45%

-533.31%

-7,257.75%

-946.17%

-245.72%

Preferred Dividend and Other Adjustments

0.44

-

-

-

-

Net Income to Common Excl. Extra Items

95.2

-56.02

-78.17

-74.77

-80.05

Basic EPS - Continuing Operations

4.2

-2.4

-3.29

-2.4

-2.33

Basic EPS - Continuing Operations Growth

+284.31%

-157.02%

-37.35%

+27.22%

+2.91%

Diluted EPS - Continuing Operations

4.06

-2.4

-3.29

-2.4

-2.33

Diluted EPS - Continuing Operations Growth

+278.04%

-159.02%

-37.35%

+27.22%

+2.91%

Basic Weighted Average Shares Outstanding

22.64

23.37

23.74

31.2

34.41

Diluted Weighted Average Shares Outstanding

23.44

23.37

23.74

31.2

34.41

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

-50.17

-54.34

-77.35

-71.04

-76.03

EBITDA Growth

+0.2%

-8.3%

-42.35%

+8.16%

-7.02%

EBITDA Margin %

-80,922.58%

-517.25%

-7,182.08%

-899.04%

-233.38%

EBIT